StockData

RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value
$5.32−0.06 (-1.12%)

Close on Nov 13, 2026Market cap $221.28MP/E –Yield –

Earnings

RxSight's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$24.60M
-18.8% on a year earlier
Adjusted net loss per share, basic and diluted, Q3 FY2026
-$0.21
-$0.04 a year earlier
Latest guidance
Raised
Jul 6, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of RxSight's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$24.60M-18.8%-$0.39-$0.21Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$33.70M+0.3%-$0.29-$0.11Release
Q1 FY2026ended Mar 31, 2026May 6, 2026during market hours$30.90M-18.5%-$0.38-$0.19Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026during market hours$32.60M-18.9%-$0.22-$0.03Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$30.30M-14.2%-$0.24-$0.04Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$33.60M-3.7%-$0.29-$0.08Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours$37.90M+28.5%-$0.20-$0.03Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025during market hours$40.20M+40.6%-$0.15$0.03Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours$35.30M+59.0%-$0.16$0.00Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024during market hours$34.90M+67.8%-$0.16–Release
Q1 FY2024ended Mar 31, 2024May 6, 2024during market hours$29.50M+68.6%-$0.25-$0.12Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

RxSight's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$140.00M – $160.00M$120.00M – $135.00MRaisedJul 6, 2026
RevenueFY2026$120.00M – $135.00M–NewFeb 25, 2026
Gross marginFY202673% – 75%70% – 72%RaisedJul 6, 2026
Gross marginFY202670% – 72%–NewFeb 25, 2026
Non-cash stock-based compensation expenseFY2026$30.00M – $32.00M–LoweredMay 6, 2026
Non-cash stock-based compensation expenseFY2026$30.00M – $32.00M–LoweredFeb 25, 2026
Operating expenseFY2026$160.00M–RaisedJul 6, 2026
Operating expensesFY2026$150.00M – $160.00M–NewMay 6, 2026
Operating expensesFY2026$150.00M – $160.00M–NewFeb 25, 2026

Guidance vs results

The last range RxSight gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$125.00M – $130.00M$134.40MΣ4QAbove range

Guidance history

Every forecast RxSight put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Jul 6, 2026Gross marginFY202673% – 75%Raised
Jul 6, 2026Operating expenseFY2026$160.00MRaised
Jul 6, 2026revenueFY2026$140.00M – $160.00MRaised
Jul 6, 2026SalesFY2026$110.00M – $120.00MLowered
Jul 6, 2026Collaboration Agreement revenueFY2026$30.00M – $40.00MLowered
May 6, 2026Gross marginFY202670% – 72%New
May 6, 2026Operating expensesFY2026$150.00M – $160.00MNew
May 6, 2026Non-cash stock-based compensation expenseFY2026$30.00M – $32.00MLowered
May 6, 2026RevenueFY2026$120.00M – $135.00MNew
Feb 25, 2026Gross marginFY202670% – 72%New
Feb 25, 2026Operating expensesFY2026$150.00M – $160.00MNew
Feb 25, 2026Non-cash stock-based compensation expenseFY2026$30.00M – $32.00MLowered
Feb 25, 2026RevenueFY2026$120.00M – $135.00MNew
Nov 5, 2025Gross marginFY202576% – 77%New
Nov 5, 2025Operating expensesFY2025$145.00M – $155.00MNew
Nov 5, 2025non-cash stock-based compensation expenseFY2025$30.00M – $32.00MLowered
Nov 5, 2025RevenueFY2025$125.00M – $130.00MNew
Aug 7, 2025Gross marginFY202572% – 74%Reaffirmed
Aug 7, 2025Operating expensesFY2025$145.00M – $155.00MRaised
Aug 7, 2025non-cash stock-based compensation expenseFY2025$27.00M – $30.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases RxSight filed with the SEC as exhibits to Form 8-K or 6-K

  1. RXSIGHT, INC. REPORTS THIRD QUARTER 2026 RESULTS
    Results
  2. RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK
    Results
  3. RXSIGHT ANNOUNCES APPOINTMENTS OF AZIZ MOTTIWALA AS CHIEF EXECUTIVE OFFICER AND RON KURTZ, MD AS CHIEF
    Update
  4. Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
    Update
  5. RXSIGHT, INC. ANNOUNCES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS AND PRODUCT PIPELINE UPDATES FOLLOWING STRATEGIC COLLABORATION AGREEMENT
    Results
  6. RXSIGHT, INC. REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES FULL-YEAR SALES OUTLOOK
    Results
  7. RXSIGHT, INC. REPORTS FOURTH QUARTER AND 2025 RESULTS; ISSUES 2026 GUIDANCE
    Results
  8. RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
    Results
  9. RXSIGHT, INC. ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION
    Update
  10. RXSIGHT, INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
    Results
  11. RXSIGHT, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
    Results
  12. RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
    Results
  13. RXSIGHT, INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
    Results
  14. RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
    Results
  15. RXSIGHT, INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS, REAFFIRMS 2025 GUIDANCE
    Results

See a number that looks wrong?